Xeltis

Xeltis is developing artificial vessels and valves that are gradually replaced by the patients own living healthy tissue.

News

Key Facts

Sector: Life Sciences
Country: Netherlands
Fund: LSP HEF 2, LSP HEF 1
Entry: 2014
Website: Xeltis
EQT Responsible Advisor: Rudy Dekeyser

An abstract close-up of intricate, branching lines resembling a neural network or leaf veins, in shades of blue.

An abstract close-up of intricate, branching lines resembling a neural network or leaf veins, in shades of blue.

News

April 7, 2026
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

Do You Want to Know More?

We are eager to explore how we can achieve great things together.